Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
ELECTRON TRANSPORT CHAIN | affect | 53 | ||||||
ELECTRON TRANSPORT CHAIN | 0.3 nmol/mg | bovine | mitochondria | NADH–Q | decrease | IC50 | 94 | |
Target | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
NADH:ubiquinone reductase | 0.3 nmol/mg | bovine | mitochondria | NADH–Q | inhibitor | IC50 | 94 | |
semiquinone | antagonist | 53 | ||||||
Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 740ug/kg (0.74mg/kg) | Agricultural and Biological Chemistry. Vol. 33, Pg. 1790, 1969. | |
mouse | LD50 | oral | 3mg/kg (3mg/kg) | Agricultural and Biological Chemistry. Vol. 33, Pg. 1790, 1969. | |
mouse | LD50 | intravenous | 1260ug/kg (1.26mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#02084, | |
mouse | LD50 | subcutaneous | 1400ug/kg (1.4mg/kg) | Journal of Antibiotics, Series A. Vol. 7, Pg. 60, 1954. | |
(+)-aureothin | 2-Methoxy-3,5-dimethyl-6-[(2R,4Z)-4-[(2E)-2-methyl-3-(4-nitrophenyl)prop-2-en-1-ylidene]oxolan-2-yl]-4H-pyran-4-one | 2-[(2R)-4-[2-Methyl-3-(4-nitrophenyl)-2-propenylidene]tetrahydrofuran-2beta-yl]-3,5-dimethyl-6-methoxy-4H-pyran-4-one |
2-methoxy-3,5-dimethyl-6-[(2R,4Z)-4-[(E)-2-methyl-3-(4-nitrophenyl)prop-2-enylidene]tetrahydrofuran-2-yl]pyran-4-one | 2-methoxy-3,5-dimethyl-6-[(2R,4Z)-tetrahydro-4-[(2E)-2-methyl-3-(4-nitrophenyl)-2-propen-1-ylidene]-2-furanyl]-4H-pyran-4-one | 2-methoxy-3,5-dimethyl-6-[(2R,5Z)-5-[(E)-2-methyl-3-(4-nitrophenyl)prop-2-enylidene]oxolan-2-yl]pyran-4-one |
2-methoxy-3,5-dimethyl-6-{(2R,4Z)-4-[(2E)-2-methyl-3-(4-nitrophenyl)prop-2-en-1-ylidene]tetrahydrofuran-2-yl}-4H-pyran-4-one; | AKOS015969696 | AKOS016023667 |
Aureothin | C15689 | CHEBI:80024 |
Q27149169 | SCHEMBL13645672 | ZINC4025640 |